and 59% were assessed as high risk. Based on our interim data analysis, we found that thrombophilia testing was done on a relatively small subset of low risk (6.8%) and high risk (22.7%) patients, which was very encouraging. At our center, the cost of testing for hereditary thrombophilia was $6,172 per patient. Even in the high-risk group, in more than half of patients who were tested for thrombophilia, testing did not change the management.
Based on current evidence and on the fact that thrombophilia testing rarely changes the management plan (even for high-risk patients), I think the testing is being overused. High-risk patients have enough high-risk indicators to justify continuation of anticoagulation regardless of thrombophilia testing results. The cost of thrombophilia testing is extremely high without, in most circumstances, having a significant effect on patient care.
